{
    "clinical_study": {
        "@rank": "15085", 
        "arm_group": {
            "arm_group_label": "polypoidal choroidal vasculopathy without polyp", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate  the efficacy and safety of aflibercept for\n      treatment of polypoidal choroidal vasculopathy without active polyp."
        }, 
        "brief_title": "Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy", 
        "condition": "Polypoidal Choroidal Vasculopathy Without Active Polyp", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  polypoidal choroidal vasculopathy without active polyp\n\n          -  decreased visual acuity by subretinal fluid and hemorrhage involving foveal center\n\n        Exclusion Criteria:\n\n          -  polypoidal choroidal vasculopathy with active polyp\n\n          -  previous photodynamic therapy more than three times\n\n          -  anti-VEGF injection within one month\n\n          -  photodynamic therapy or intraocular steroid treatment within three months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072408", 
            "org_study_id": "2013-10-044-002"
        }, 
        "intervention": {
            "arm_group_label": "polypoidal choroidal vasculopathy without polyp", 
            "description": "Three monthly intravitreal aflibercept (2mg) injections\nFive bimonthly intravitreal aflibercept (2mg) injections\nRescue treatment: Verteporfin photodynamic therapy\nLoss of five ETDRS letters or one Snellen line of vision from baseline\nPresence of subretinal fluid or intraretinal fluid despite three consecutive  (monthly or bimonthly) aflibercept injection\nPresence of active polyp on indocyanine green angiography", 
            "intervention_name": "aflibercept", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Endothelial Growth Factors"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Kyu Hyung Park, M.D.", 
                    "phone": "82-32-787-7373"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyunggi-do"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "investigator": {
                    "last_name": "Kyu Hyung Park, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Se Woong Kang, MD", 
                    "phone": "02-3410-3548"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Se Woong Kang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tae Gon Lee, M.D.", 
                    "phone": "82-2-3410-3548"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Konyang University Kim's Eye Hospital"
                }, 
                "investigator": {
                    "last_name": "Tae Gon Lee, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "last_name": "Se Woong Kang, MD", 
            "phone": "82-2-3410-3548"
        }, 
        "overall_contact_backup": {
            "last_name": "Ga Eun Cho, MD", 
            "phone": "82-10-2502-2436"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of best-corrected visual acuity (ETDRS letters)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total number of months when subretinal hemorrhage are detected on fundus photographs.", 
                "measure": "presence of subretinal hemorrhage", 
                "safety_issue": "No", 
                "time_frame": "during 1 year"
            }, 
            {
                "description": "Total number of months when fluid in macula are detected on optical coherence tomography", 
                "measure": "presence of fluid in macula evidenced by optical coherence tomography", 
                "safety_issue": "No", 
                "time_frame": "during 1 year"
            }, 
            {
                "description": "Change of indocyanine green angiography will include followings\nNew appearance of polypoidal structure\nAny change in size of the greatest linear dimension of lesion\nAny change in size and activity of branching vascular network", 
                "measure": "change of indocyanine green angiography", 
                "safety_issue": "No", 
                "time_frame": "during 1 year"
            }, 
            {
                "description": "In this study, photodynamic therapy will be performed as a rescue therapy according to the necessary criteria.", 
                "measure": "Number of eyes which need rescue treatment (photodynamic therapy)", 
                "safety_issue": "No", 
                "time_frame": "during 1 year"
            }, 
            {
                "description": "frequency and severity of ocular adverse event", 
                "measure": "safety outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Seoul National University Bundang Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kim's Eye Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bayer", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}